Monoamine Oxidase Inhibitors (Maois)

Do not use if currently taking an MAOI or within 2 weeks of stopping MAOI therapy. Includes drugs for depression, psychiatric/emotional conditions, or Parkinson's disease.

Do not use if taking a prescription MAOI or for 2 weeks after stopping an MAOI drug. MAOIs used for depression, psychiatric conditions, or Parkinson's disease are contraindicated.

Contraindicated with amitriptyline; see contraindications section.

Concurrent usage of tricyclic antidepressants and monoamine oxidase inhibitors is contraindicated.

Serious, sometimes fatal reactions including hyperthermia, rigidity, myoclonus, autonomic instability, and mental status changes may occur when combined with MAOIs.

Serious, sometimes fatal reactions including hyperthermia, rigidity, myoclonus, autonomic instability, and mental status changes when combined with MAOIs.

Hypertensive crises have resulted when sympathomimetic amines used concomitantly or within 14 days following use of monoamine oxidase inhibitors.

Hyperpyrexia, hypotension, and death reported with coadministration. MAO inhibitors prolong/intensify anticholinergic effects and enhance pseudoephedrine effect.

Concomitant administration should be avoided. MAO inhibitors prolong and intensify anticholinergic effects of brompheniramine and may enhance pseudoephedrine effects.

Hyperpyrexia, hypotension, and death reported with coadministration. MAO inhibitors prolong anticholinergic effects and enhance sympathomimetic effects.

Concomitant use or use within 14 days of stopping treatment is contraindicated due to increased risk of serotonin syndrome and/or elevated blood pressure.

Increased risk of serotonin syndrome and/or elevated blood pressure. Contraindicated within 14 days of stopping either drug.

No information available on concurrent use; patient advised to avoid concomitant use.

MAOIs prolong and intensify the anticholinergic (drying) effects of carbinoxamine. Do not use concomitantly.

Contraindicated use with citalopram per CONTRAINDICATIONS and WARNINGS sections.

Concomitant use increases risk of serotonin syndrome. Citalopram is contraindicated in patients taking MAOIs.

MAO inhibitors potentiate the effect of pseudoephedrine on the vascular system. Do not use within 14 days of stopping MAO inhibitor therapy.

Contraindicated; deutetrabenazine should not be used with MAOIs or within 14 days of discontinuing MAOI therapy.

Concomitant use can cause hypertensive crisis with potential outcomes including death, stroke, myocardial infarction, aortic dissection, and renal failure.

Concomitant use can cause hypertensive crisis with potentially fatal outcomes including death, stroke, myocardial infarction, and aortic dissection. Do not use concomitantly or within 14 days of MAOI discontinuation.

Concomitant use can cause hypertensive crisis with potentially fatal outcomes including death, stroke, myocardial infarction, aortic dissection, and renal failure. Do not administer together.

Do not use if currently taking a prescription MAOI or within 2 weeks after stopping an MAOI drug. Risk of serious adverse effects.

Do not use NUEDEXTA with MAOIs or in patients who have taken MAOIs within the preceding 14 days.

Hypertension may result when diethylpropion is used with MAO inhibitors due to monoamine interaction.

MAOIs may interact with diphenoxylate and precipitate hypertensive crisis. Avoid use and monitor for signs including headache, hyperthermia, and hypertension.

Concomitant use increases risk of serotonin syndrome. Use within 14 days of MAOI discontinuation is contraindicated.

Use is contraindicated; MAOIs prolong and intensify the anticholinergic (drying) effects of antihistamines.

Use is contraindicated in women taking MAOIs, which prolong and intensify the anticholinergic (drying) effects of antihistamines.

MAOIs are contraindicated with escitalopram due to risk of serotonin syndrome.

Concomitant use with MAOIs is contraindicated due to risk of serious adverse reactions including serotonin syndrome.

Contraindicated combination with fluoxetine due to risk of serotonin syndrome.

MAOIs are contraindicated with fluoxetine due to risk of serious adverse effects.

Can potentiate the effects of hydrocodone. Avoid concomitant use in patients receiving MAOIs or within 14 days of stopping an MAOI.

Can potentiate the effects of hydrocodone. Avoid concomitant use in patients receiving MAOIs or within 14 days of stopping an MAOI.

Concomitant use increases risk of serotonin syndrome. Contraindicated with MAOIs intended to treat psychiatric disorders or within 14 days of stopping MAOI treatment.

Linezolid is a reversible, nonselective inhibitor of monoamine oxidase and is contraindicated with MAOIs due to potential serious interactions.

Meperidine is contraindicated with MAOIs or within 14 days of stopping them. Can cause unpredictable, severe, and occasionally fatal reactions including serotonin syndrome, respiratory depression, coma, and hypertensive crisis.

Methamphetamine hydrochloride should not be used concurrently with monoamine oxidase inhibitors.

Concomitant use can cause hypertensive crisis with potentially fatal outcomes including death, stroke, myocardial infarction, and aortic dissection. Contraindicated within 14 days of MAOI discontinuation.

Concomitant use can cause hypertensive crisis with potential outcomes including death, stroke, myocardial infarction, aortic dissection, and renal failure.

Increased risk of hypertension. Avoid concomitant use.

Increased risk of hypertension. Avoid concomitant use.

Concomitant use with midodrine should be avoided.

Concomitant use increases risk of serotonin syndrome. Use of MAOIs with SAVELLA or within 5 days of stopping SAVELLA is contraindicated.

Monoamine Oxidase Inhibitors are contraindicated with mirtazapine; see contraindications, warnings, and dosage sections.

Do not use within 14 days of stopping MAOI treatment; may manifest as serotonin syndrome or opioid toxicity including respiratory depression and coma.

Concomitant use is contraindicated. Bupropion inhibits re-uptake of dopamine and norepinephrine, increasing risk of hypertensive reactions with MAOIs. At least 14 days must elapse between discontinuation of MAOI and initiation of CONTRAVE, and vice versa.

MAOIs are contraindicated with olanzapine and fluoxetine combination due to risk of serious adverse effects.

MAOIs intensify opioid effects causing anxiety, confusion, significant respiratory depression or coma. Not recommended for patients taking MAOIs or within 14 days of stopping.

Not recommended; may manifest as serotonin syndrome or opioid toxicity including respiratory depression and coma.

Contraindicated due to risk of serotonin syndrome.

Contraindicated based on CONTRAINDICATIONS and WARNINGS sections.

Concomitant use is contraindicated due to risk of serotonin syndrome.

Contraindicated during or within 14 days of MAOi use due to risk of hypertensive crisis.

Concomitant use increases risk of hypertensive crisis. Contraindicated during MAOI treatment and within 14 days of stopping an MAOI.

Concomitant use of phentermine with MAOIs increases the risk of hypertensive crisis. Contraindicated during MAOI treatment and within 14 days of stopping an MAOI.

Contraindicated during or within 14 days of MAOI administration due to risk of hypertensive crisis.

Hyperpyrexia, hypotension, and death reported with co-administration. Increased extrapyramidal effects when MAO inhibitors used with phenothiazines. Concomitant administration should be avoided.

May manifest as serotonin syndrome or opioid toxicity. Not recommended for patients taking MAOIs or within 14 days of stopping treatment.

Rizatriptan is contraindicated in patients taking MAO-A inhibitors due to increased systemic exposure of rizatriptan and metabolite.

Rizatriptan is contraindicated in patients taking non-selective MAO inhibitors.

Concomitant use can cause hypertensive crisis with potential for death, stroke, myocardial infarction, aortic dissection, and other serious complications.

Concomitant use increases risk of serotonin syndrome. Sertraline HCl Capsules is contraindicated in patients taking MAOIs.

Do not administer SUNOSI concomitantly with MAOIs or within 14 days after discontinuing MAOI treatment. Concomitant use may increase risk of hypertensive reaction with serious outcomes including death, stroke, myocardial infarction, and aortic dissection.

MAO-A inhibitors increase systemic exposure of sumatriptan 7-fold. Use is contraindicated.

Tetrabenazine is contraindicated in patients taking MAOIs. Minimum 14 days must elapse after discontinuing MAOI before starting tetrabenazine.

Concomitant use may increase monoamine neurotransmitter concentration in synapses, potentially leading to serotonin syndrome or attenuated treatment effect. Avoid use or within 14 days of discontinuing MAOI therapy.

Concomitant use increases risk of serotonin syndrome. Contraindicated in patients taking MAOIs.

Concomitant use increases risk of serotonin syndrome. Contraindicated in patients taking MAOIs.

Concomitant use increases risk of serotonin syndrome. Vilazodone hydrochloride is contraindicated in patients taking MAOIs.

Concomitant use may lead to potentially life-threatening hypertensive crisis. Concomitant use or use within 2 weeks after discontinuing an MAOI is contraindicated.

Dihydrocodeine causes CNS excitation and hypertension when combined with MAOIs.

May potentiate effect of formoterol on cardiovascular system. Use with extreme caution.

MAOIs may potentiate the effects of epinephrine.

Albuterol should be administered with extreme caution; the action of albuterol on the vascular system may be potentiated.

May potentiate cardiovascular effects of albuterol. Use with extreme caution or consider alternative therapy.

Use with extreme caution due to potential cardiovascular effects.

May potentiate cardiovascular effects of arformoterol. Should be administered with extreme caution.

May produce severe, prolonged hypertension when combined with local anesthetic solutions containing epinephrine.

May produce severe, prolonged hypertension when local anesthetic solutions containing epinephrine are administered to patients receiving MAOIs.

Use of atropine with MAOIs is generally not recommended due to potential to precipitate hypertensive crisis.

May produce severe, prolonged hypertension. Concurrent use should generally be avoided.

May result in increased hypotension when used with brimonidine tartrate and timolol maleate.

May potentiate the effect of formoterol on the vascular system. Use with extreme caution or within 2 weeks of discontinuation.

Administration may produce severe, prolonged hypertension. Concurrent use should generally be avoided.

May produce severe, prolonged hypertension. Concurrent use should generally be avoided; if necessary, careful hemodynamic monitoring is essential.

Increased risk of hypertensive reactions when used concomitantly with bupropion.

Increased risk of hypertensive reactions when used concomitantly with bupropion.

Increased risk of hypertensive reactions when used concomitantly with bupropion.

MAO inhibitors may enhance the CNS effects of butalbital.

CNS effects of butalbital may be enhanced by MAO inhibitors.

May increase risk of hypotension and/or severe bradycardia through catecholamine depletion combined with beta-blockade.

Catecholamine-depleting agents that may increase risk of hypotension and severe bradycardia when combined with carvedilol.

Concurrent use with local anesthetic solutions containing epinephrine or norepinephrine may produce severe, prolonged hypotension or hypertension.

MAOIs potentiate CNS-depressant action of clonazepam.

Actions of benzodiazepines may be potentiated by monoamine oxidase inhibitors.

Concomitant administration may potentiate the effects and toxicity of monoamine-oxidase inhibitors.

Administration with Bupivacaine Hydrochloride and Epinephrine may produce severe, prolonged hypertension. Concurrent use should generally be avoided.

Concurrent use may precipitate a hypertensive crisis due to structural similarity to meperidine.

Inhibition of MAO prolongs and potentiates dopamine effects. Initial dopamine dose should not exceed 1/10 of usual dose if given within 2-3 weeks of MAO inhibitor treatment.

Potentiate pressor effects of epinephrine.

Effects of epinephrine may be potentiated by monoamine oxidase inhibitors.

Effects of epinephrine may be potentiated by monoamine oxidase inhibitors.

May potentiate effect of vilanterol on cardiovascular system, with increased risk of cardiovascular adverse effects.

May potentiate effect of vilanterol on cardiovascular system. Use with extreme caution, especially within 2 weeks of discontinuation.

Use with extreme caution; may potentiate salmeterol effects on the vascular system.

Effect of formoterol on cardiovascular system may be potentiated. Use with extreme caution.

May potentiate formoterol effects on vascular system. Use with extreme caution and avoid within 2 weeks of discontinuation.

Monoamine oxidase inhibitors may potentiate the hypoglycemic action of glyburide. Close observation for hypoglycemia required.

Use with extreme caution. May potentiate cardiovascular effects of formoterol.

Can potentiate the effects of hydrocodone. Avoid concomitant use in patients receiving MAOIs or within 14 days of stopping an MAOI.

May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

Extreme caution advised; action of albuterol on cardiovascular system may be potentiated. Should not be used within 2 weeks of MAOi discontinuation.

May potentiate clinical response of isoproterenol; hemodynamic parameters may be significantly affected.

May produce severe, prolonged hypertension. Concurrent use should generally be avoided.

Levalbuterol should be administered with extreme caution to patients being treated with MAOIs or within 2 weeks of discontinuation due to risk of potentiating cardiovascular effects.

Levalbuterol should be administered with extreme caution to patients on MAOIs or within 2 weeks of discontinuation due to potential potentiation of cardiovascular effects.

May potentiate cardiovascular effects of levalbuterol. Administer with extreme caution or within 2 weeks of discontinuation.

May potentiate effects of levalbuterol on the cardiovascular system. Use with extreme caution or consider alternative therapy.

Concomitant use has resulted in serotonin syndrome.

Administration of lidocaine solutions containing epinephrine may produce severe, prolonged hypertension. Concurrent use should generally be avoided.

May produce severe prolonged hypotension or hypertension. Concurrent use should generally be avoided; careful monitoring essential if necessary.

Administration with Bupivacaine Hydrochloride and Epinephrine may produce severe, prolonged hypertension. Concurrent use should generally be avoided.

Concomitant administration can precipitate serotonin syndrome. Monitor for signs and symptoms, particularly during lithium initiation.

Administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving MAOIs may produce severe, prolonged hypertension.

Concurrent use with vasopressor-containing local anesthetic solutions may produce severe, prolonged hypertension.

Concomitant use may result in serotonin syndrome. Carefully observe patient during treatment initiation and dosage modification; discontinue metaxalone if serotonin syndrome occurs.

Can potentiate the effects of methadone. Avoid concomitant use or within 14 days of stopping MAOI treatment.

Concomitant use may result in serotonin syndrome with serious CNS reactions, potentially fatal.

Administration of Bupivacaine Hydrochloride and Epinephrine to patients receiving MAOIs may produce severe, prolonged hypertension. Concurrent use should generally be avoided.

Catecholamine-depleting drugs with additive effect causing hypotension, marked bradycardia, vertigo, syncope, or postural hypotension.

Catecholamine-depleting drugs may have additive effect with metoprolol, causing hypotension, marked bradycardia, vertigo, syncope, or postural hypotension.

Catecholamine depleting drugs with additive effect when given with metoprolol succinate ER, may cause hypotension or marked bradycardia with vertigo, syncope, or postural hypotension.

Catecholamine-depleting drugs with additive effect; may cause hypotension, marked bradycardia, vertigo, syncope, or postural hypotension.

Catecholamine-depleting drugs that may have additive effect with metoprolol, increasing risk of hypotension or bradycardia.

Co-administration can cause severe, prolonged hypertension. Monitor for hypertension if administration cannot be avoided.

May potentiate action of olodaterol on cardiovascular system. Administer with extreme caution.

Concomitant use may cause CNS excitation and hypertension through effects on catecholamines. Avoid use within 14 days of MAOI discontinuation.

MAOIs prolong the effects of barbiturates by inhibiting barbiturate metabolism.

MAOIs prolong effects of barbiturates. Barbiturate metabolism is inhibited, requiring careful monitoring.

Agonistic effects increase phenylephrine blood pressure effect.

May produce severe, prolonged hypotension or hypertension; concurrent use should generally be avoided.

Concomitant use with MAOIs and phenothiazines may result in increased incidence of extrapyramidal effects; possibility should be considered.

MAOI with promethazine increases incidence of extrapyramidal effects. MAOI with phenylephrine may cause acute hypertensive crisis with potentiated cardiac pressor response.

May potentiate salmeterol's effects on the vascular system, increasing risk of cardiovascular adverse effects.

Administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving MAOIs may produce severe, prolonged hypertension.

Terbutaline action on the vascular system may be potentiated when used with MAOIs or within 2 weeks of discontinuation.

MAO inhibitors may potentiate the action of adrenergic agonists on the cardiovascular system. Use with extreme caution.

Severe, prolonged hypertension may occur with local anesthetic solutions containing epinephrine.

Use with extreme caution. May potentiate vilanterol's effect on cardiovascular system, increasing risk of adverse cardiac events.

Caution should be used when concomitantly administering MAO inhibitors and armodafinil.

May potentiate the effects of epinephrine.

MAO inhibitors may interfere with brimonidine metabolism, potentially resulting in increased systemic side effects such as hypotension.

May interfere with brimonidine metabolism and potentially result in increased systemic side effects such as hypotension; caution advised.

May interfere with brimonidine metabolism and potentially result in increased hypotension and systemic side effects; caution is advised.

May theoretically interfere with brimonidine metabolism and potentially increase systemic side effects such as hypotension.

MAO inhibitors may enhance the CNS effects of butalbital.

MAO inhibitors may enhance the CNS effects of butalbital.

MAO inhibitors may enhance the CNS effects of butalbital.

MAO inhibitors may theoretically increase brimonidine metabolism interference and result in increased systemic hypotension. Caution advised.

MAO inhibitors prolong and intensify the anticholinergic effects of antihistamines.

Additive pressor effect may result from concurrent administration with doxapram.

Augments the pressor effect of ephedrine. Carefully monitor blood pressure.

Concomitant use may increase blood pressure. Closely monitor blood pressure with concomitant use.

May potentiate the action of estazolam; careful consideration of CNS effects needed.

May interfere with Fluorodopa F18 imaging. Consider discontinuing 12 hours before administration if safely possible.

May potentiate hypoglycemic action of glyburide; patient should be closely observed for hypoglycemia.

May increase glucose-lowering effect of glimepiride, increasing susceptibility to hypoglycemia.

MAOIs may potentiate hypoglycemic action of glipizide. Patient should be observed closely for hypoglycemia when initiated or withdrawn.

MAOIs may potentiate the hypoglycemic action of glipizide. Patient should be observed closely for hypoglycemia.

May potentiate hypoglycemic action of glyburide; monitor for hypoglycemia.

Additive adverse effects from cholinergic blockade may occur when combined with hyoscyamine sulfate.

May increase risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.

May increase risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.

May increase risk of hypoglycemia; dosage reductions and increased glucose monitoring may be required.

May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

May increase the risk of hypoglycemia. Dose reductions and increased frequency of glucose monitoring may be required.

May increase risk of hypoglycemia. Dosage reductions and increased frequency of glucose monitoring may be required.

May increase risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.

May increase risk of hypoglycemia; dose adjustment and increased glucose monitoring may be required.

May increase risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.

May increase risk of hypoglycemia. Dose reductions and increased glucose monitoring may be required.

Catecholamine depletor; additive effect with beta-blockers may increase risk of hypotension, marked bradycardia, vertigo, syncope, or postural hypotension. Monitor blood pressure and heart rate.

Concurrent use may intensify antimuscarinic side effects.

Concurrent use with hyoscyamine may intensify antimuscarinic side effects.

Catecholamine-depleting drug may have additive effect with metoprolol, increasing risk of hypotension or marked bradycardia.

Caution should be used when concomitantly administering MAO inhibitors and modafinil.

May increase blood-glucose-lowering effect of nateglinide and susceptibility to hypoglycemia. Dose reductions and increased glucose monitoring may be required.

MAO inhibitors can affect metabolism and uptake of circulating amines; caution is advised.

MAOIs prolong barbiturate effects by inhibiting barbiturate metabolism.

May increase susceptibility to hypoglycemia when coadministered with SYMLIN. Use with caution.

The hypotensive effect of MAO inhibitors may be exacerbated when administered with propranolol. Monitor for postural hypotension.

May enhance neuromuscular blocking effect through plasma cholinesterase inhibition.

May intensify anticholinergic effects of trihexyphenidyl due to secondary anticholinergic activities.

Concurrent use may intensify antimuscarinic side effects.